Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 8316 | 2.39 |
09:34 ET | 3765 | 2.37 |
09:36 ET | 51528 | 2.38 |
09:38 ET | 1641 | 2.37 |
09:39 ET | 1520 | 2.39 |
09:41 ET | 3406 | 2.41 |
09:43 ET | 2906 | 2.425 |
09:45 ET | 740 | 2.43 |
09:48 ET | 600 | 2.44 |
09:50 ET | 100 | 2.45 |
09:52 ET | 500 | 2.44 |
09:54 ET | 1478 | 2.44 |
09:57 ET | 500 | 2.43 |
09:59 ET | 6821 | 2.43 |
10:01 ET | 1400 | 2.425 |
10:03 ET | 24128 | 2.425 |
10:06 ET | 21903 | 2.415 |
10:08 ET | 3426 | 2.415 |
10:10 ET | 700 | 2.415 |
10:12 ET | 1300 | 2.415 |
10:14 ET | 7468 | 2.405 |
10:15 ET | 500 | 2.405 |
10:17 ET | 6896 | 2.39 |
10:19 ET | 400 | 2.39 |
10:21 ET | 4334 | 2.385 |
10:24 ET | 200 | 2.385 |
10:26 ET | 1300 | 2.385 |
10:28 ET | 700 | 2.385 |
10:30 ET | 2465 | 2.385 |
10:32 ET | 270 | 2.39 |
10:33 ET | 7415 | 2.385 |
10:35 ET | 2298 | 2.38 |
10:37 ET | 2133 | 2.385 |
10:39 ET | 4808 | 2.37 |
10:42 ET | 1192 | 2.37 |
10:44 ET | 1500 | 2.37 |
10:46 ET | 1534 | 2.375 |
10:48 ET | 400 | 2.375 |
10:50 ET | 400 | 2.375 |
10:53 ET | 200 | 2.375 |
10:55 ET | 5331 | 2.365 |
10:57 ET | 4108 | 2.355 |
11:00 ET | 7952 | 2.35 |
11:02 ET | 53449 | 2.34 |
11:04 ET | 7640 | 2.34 |
11:06 ET | 18168 | 2.355 |
11:08 ET | 7949 | 2.35 |
11:09 ET | 2086 | 2.36 |
11:11 ET | 200 | 2.355 |
11:13 ET | 100 | 2.355 |
11:15 ET | 1143 | 2.35 |
11:18 ET | 16229 | 2.34 |
11:20 ET | 14583 | 2.34 |
11:22 ET | 2639 | 2.34 |
11:24 ET | 6038 | 2.33 |
11:26 ET | 3945 | 2.33 |
11:27 ET | 2008 | 2.335 |
11:29 ET | 1074 | 2.335 |
11:31 ET | 4789 | 2.335 |
11:33 ET | 6489 | 2.335 |
11:36 ET | 300 | 2.335 |
11:38 ET | 23250 | 2.32 |
11:40 ET | 4352 | 2.32 |
11:42 ET | 20923 | 2.31 |
11:44 ET | 3312 | 2.315 |
11:45 ET | 8917 | 2.325 |
11:47 ET | 714 | 2.325 |
11:49 ET | 3575 | 2.325 |
11:51 ET | 11574 | 2.325 |
11:54 ET | 19426 | 2.31 |
11:56 ET | 2035 | 2.315 |
11:58 ET | 24434 | 2.315 |
12:00 ET | 616 | 2.315 |
12:02 ET | 6059 | 2.325 |
12:03 ET | 300 | 2.325 |
12:05 ET | 400 | 2.325 |
12:07 ET | 700 | 2.325 |
12:09 ET | 5958 | 2.326 |
12:12 ET | 4873 | 2.32 |
12:14 ET | 1513 | 2.325 |
12:16 ET | 6878 | 2.31 |
12:18 ET | 600 | 2.315 |
12:20 ET | 4719 | 2.33 |
12:21 ET | 3042 | 2.325 |
12:23 ET | 1849 | 2.32 |
12:25 ET | 100 | 2.325 |
12:27 ET | 200 | 2.32 |
12:30 ET | 545 | 2.33 |
12:32 ET | 4205 | 2.335 |
12:34 ET | 2870 | 2.34 |
12:36 ET | 200 | 2.33 |
12:38 ET | 4534 | 2.345 |
12:39 ET | 400 | 2.345 |
12:41 ET | 1206 | 2.345 |
12:43 ET | 62696 | 2.365 |
12:45 ET | 700 | 2.365 |
12:48 ET | 2375 | 2.375 |
12:50 ET | 764 | 2.375 |
12:52 ET | 997 | 2.37 |
12:54 ET | 1452 | 2.375 |
12:56 ET | 1700 | 2.375 |
12:57 ET | 3290 | 2.38 |
12:59 ET | 11307 | 2.37 |
01:01 ET | 2603 | 2.365 |
01:03 ET | 3602 | 2.36 |
01:06 ET | 68343 | 2.36 |
01:08 ET | 1800 | 2.365 |
01:10 ET | 20840 | 2.355 |
01:12 ET | 728 | 2.355 |
01:14 ET | 5111 | 2.355 |
01:15 ET | 600 | 2.355 |
01:17 ET | 404 | 2.35 |
01:19 ET | 606 | 2.355 |
01:21 ET | 2091 | 2.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 1.0B | -1.1x | --- |
CARGO Therapeutics Inc | 1.0B | -5.3x | --- |
Cullinan Therapeutics Inc | 1.0B | -5.4x | --- |
Enliven Therapeutics Inc | 1.1B | -12.7x | --- |
Sana Biotechnology Inc | 994.4M | -3.6x | --- |
Praxis Precision Medicines Inc | 1.1B | -5.6x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 334.8M |
Nuvation Bio Inc does not pay a dividend. | |
Beta | 1.37 |
EPS | $-2.11 |
Book Value | $2.76 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 716.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37,474.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.